nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—CYP3A4—bone cancer	0.447	1	CbGaD
Ruxolitinib—PRKCE—tendon—bone cancer	0.00275	0.027	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—bone cancer	0.00264	0.0259	CbGeAlD
Ruxolitinib—JAK3—connective tissue—bone cancer	0.00247	0.0243	CbGeAlD
Ruxolitinib—JAK1—connective tissue—bone cancer	0.00246	0.0241	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—bone cancer	0.0023	0.0225	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—bone cancer	0.00212	0.0208	CbGeAlD
Ruxolitinib—CAMK1—tendon—bone cancer	0.00206	0.0202	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—bone cancer	0.00206	0.0202	CbGeAlD
Ruxolitinib—MARK2—tendon—bone cancer	0.002	0.0196	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—bone cancer	0.00199	0.0195	CbGeAlD
Ruxolitinib—TAOK2—tendon—bone cancer	0.00185	0.0182	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—bone cancer	0.00184	0.0181	CbGeAlD
Ruxolitinib—JAK1—tendon—bone cancer	0.00169	0.0166	CbGeAlD
Ruxolitinib—DCLK1—tendon—bone cancer	0.00169	0.0166	CbGeAlD
Ruxolitinib—Myelosuppression—Cisplatin—bone cancer	0.00169	0.0645	CcSEcCtD
Ruxolitinib—MAP3K2—connective tissue—bone cancer	0.00167	0.0164	CbGeAlD
Ruxolitinib—CAMK1D—tendon—bone cancer	0.00165	0.0162	CbGeAlD
Ruxolitinib—PHKG2—tendon—bone cancer	0.00164	0.0161	CbGeAlD
Ruxolitinib—JAK1—bone marrow—bone cancer	0.00164	0.0161	CbGeAlD
Ruxolitinib—JAK1—spinal cord—bone cancer	0.00163	0.016	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—bone cancer	0.00163	0.016	CbGeAlD
Ruxolitinib—PLK4—bone marrow—bone cancer	0.00163	0.016	CbGeAlD
Ruxolitinib—TYK2—connective tissue—bone cancer	0.00163	0.016	CbGeAlD
Ruxolitinib—DAPK2—tendon—bone cancer	0.00161	0.0158	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—bone cancer	0.0016	0.0158	CbGeAlD
Ruxolitinib—STK16—tendon—bone cancer	0.00159	0.0156	CbGeAlD
Ruxolitinib—HIPK2—tendon—bone cancer	0.00158	0.0155	CbGeAlD
Ruxolitinib—RET—connective tissue—bone cancer	0.00156	0.0154	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—bone cancer	0.00156	0.0153	CbGeAlD
Ruxolitinib—DAPK2—spinal cord—bone cancer	0.00155	0.0153	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—bone cancer	0.00152	0.0149	CbGeAlD
Ruxolitinib—DAPK3—tendon—bone cancer	0.00152	0.0149	CbGeAlD
Ruxolitinib—CLK2—tendon—bone cancer	0.0015	0.0147	CbGeAlD
Ruxolitinib—JAK2—connective tissue—bone cancer	0.00148	0.0145	CbGeAlD
Ruxolitinib—DAPK3—spinal cord—bone cancer	0.00146	0.0144	CbGeAlD
Ruxolitinib—CLK2—bone marrow—bone cancer	0.00145	0.0143	CbGeAlD
Ruxolitinib—BMPR2—tendon—bone cancer	0.00141	0.0139	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—bone cancer	0.00131	0.0128	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—bone cancer	0.0013	0.0128	CbGeAlD
Ruxolitinib—BMP2K—tendon—bone cancer	0.00127	0.0124	CbGeAlD
Ruxolitinib—CAMK2G—tendon—bone cancer	0.00127	0.0124	CbGeAlD
Ruxolitinib—LRRK2—tendon—bone cancer	0.00125	0.0123	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—bone cancer	0.00123	0.012	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—bone cancer	0.00123	0.012	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—bone cancer	0.00122	0.012	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—bone cancer	0.00122	0.012	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—bone cancer	0.00121	0.0119	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—bone cancer	0.00121	0.0119	CbGeAlD
Ruxolitinib—MAP3K7—tendon—bone cancer	0.00114	0.0112	CbGeAlD
Ruxolitinib—TYK2—tendon—bone cancer	0.00112	0.011	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—bone cancer	0.00111	0.0109	CbGeAlD
Ruxolitinib—MKNK2—tendon—bone cancer	0.0011	0.0108	CbGeAlD
Ruxolitinib—IRAK1—tendon—bone cancer	0.0011	0.0108	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—bone cancer	0.0011	0.0108	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—bone cancer	0.0011	0.0108	CbGeAlD
Ruxolitinib—TYK2—bone marrow—bone cancer	0.00108	0.0106	CbGeAlD
Ruxolitinib—TYK2—spinal cord—bone cancer	0.00108	0.0106	CbGeAlD
Ruxolitinib—RET—tendon—bone cancer	0.00108	0.0106	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—bone cancer	0.00107	0.0105	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—bone cancer	0.00107	0.0105	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—bone cancer	0.00106	0.0104	CbGeAlD
Ruxolitinib—RET—spinal cord—bone cancer	0.00104	0.0102	CbGeAlD
Ruxolitinib—JAK2—tendon—bone cancer	0.00102	0.00998	CbGeAlD
Ruxolitinib—JAK2—bone marrow—bone cancer	0.000985	0.00967	CbGeAlD
Ruxolitinib—JAK2—spinal cord—bone cancer	0.000981	0.00963	CbGeAlD
Ruxolitinib—MAP3K3—tendon—bone cancer	0.00098	0.00962	CbGeAlD
Ruxolitinib—Infection—Carboplatin—bone cancer	0.000957	0.0365	CcSEcCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—bone cancer	0.000951	0.081	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—bone cancer	0.000951	0.081	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—bone cancer	0.000951	0.081	CbGdCrCtD
Ruxolitinib—MAP3K3—bone marrow—bone cancer	0.000949	0.00932	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—bone cancer	0.000945	0.00928	CbGeAlD
Ruxolitinib—TAOK3—tendon—bone cancer	0.000893	0.00877	CbGeAlD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—bone cancer	0.00088	0.0749	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—bone cancer	0.00088	0.0749	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—bone cancer	0.00088	0.0749	CbGdCrCtD
Ruxolitinib—Myelosuppression—Epirubicin—bone cancer	0.000868	0.0331	CcSEcCtD
Ruxolitinib—TAOK3—bone marrow—bone cancer	0.000865	0.00849	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—bone cancer	0.000862	0.00846	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—bone cancer	0.000803	0.0306	CcSEcCtD
Ruxolitinib—Body temperature increased—Carboplatin—bone cancer	0.000762	0.0291	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—bone cancer	0.00065	0.0553	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—bone cancer	0.00065	0.0553	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—bone cancer	0.00065	0.0553	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—bone cancer	0.00065	0.0553	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—bone cancer	0.00065	0.0553	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—bone cancer	0.000601	0.0512	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—bone cancer	0.000601	0.0512	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—bone cancer	0.000601	0.0512	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—bone cancer	0.000601	0.0512	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—bone cancer	0.000601	0.0512	CbGdCrCtD
Ruxolitinib—Herpes zoster—Methotrexate—bone cancer	0.000577	0.022	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.000575	0.0219	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—bone cancer	0.00054	0.0206	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—bone cancer	0.0005	0.0191	CcSEcCtD
Ruxolitinib—Pancytopenia—Cisplatin—bone cancer	0.000472	0.018	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—bone cancer	0.000425	0.0162	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Cisplatin—bone cancer	0.000419	0.016	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—bone cancer	0.000393	0.015	CcSEcCtD
Ruxolitinib—Malnutrition—Cisplatin—bone cancer	0.000346	0.0132	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—bone cancer	0.000341	0.013	CcSEcCtD
Ruxolitinib—Anaemia—Cisplatin—bone cancer	0.00032	0.0122	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000295	0.0113	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000293	0.0112	CcSEcCtD
Ruxolitinib—Infection—Cisplatin—bone cancer	0.000281	0.0107	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—bone cancer	0.000277	0.0106	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—bone cancer	0.000277	0.0106	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—bone cancer	0.000275	0.0105	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000273	0.0104	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000261	0.00994	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—bone cancer	0.000259	0.00988	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—bone cancer	0.000255	0.00973	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000244	0.00931	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—bone cancer	0.000243	0.00928	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—bone cancer	0.000243	0.00928	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—bone cancer	0.000242	0.00925	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000241	0.0092	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—bone cancer	0.000239	0.00911	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—bone cancer	0.000232	0.00886	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—bone cancer	0.000232	0.00885	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—bone cancer	0.000231	0.00881	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—bone cancer	0.00023	0.00878	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—bone cancer	0.000229	0.00875	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—bone cancer	0.000228	0.00868	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—bone cancer	0.000228	0.00868	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—bone cancer	0.000224	0.00856	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—bone cancer	0.000223	0.00853	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—bone cancer	0.000221	0.00844	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—bone cancer	0.000221	0.00843	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—bone cancer	0.000219	0.00837	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—bone cancer	0.000218	0.00833	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—bone cancer	0.000217	0.00828	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—bone cancer	0.000215	0.00821	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—bone cancer	0.000215	0.0082	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—bone cancer	0.000215	0.00819	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—bone cancer	0.000214	0.00815	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—bone cancer	0.000211	0.00804	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—bone cancer	0.000211	0.00804	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—bone cancer	0.000205	0.00784	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—bone cancer	0.000205	0.00781	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—bone cancer	0.000204	0.0078	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—bone cancer	0.000203	0.00774	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—bone cancer	0.000201	0.00766	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000199	0.0076	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—bone cancer	0.000199	0.00758	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—bone cancer	0.00019	0.00725	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—bone cancer	0.00019	0.00725	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—bone cancer	0.000189	0.00721	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—bone cancer	0.000178	0.00679	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—bone cancer	0.000176	0.0067	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—bone cancer	0.000175	0.00669	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—bone cancer	0.000165	0.00628	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—bone cancer	0.000164	0.00627	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—bone cancer	0.000162	0.00619	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000161	0.00613	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—bone cancer	0.000154	0.00588	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—bone cancer	0.000152	0.0058	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—bone cancer	0.000152	0.0058	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—bone cancer	0.000152	0.00579	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—bone cancer	0.000151	0.00575	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00015	0.00574	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—bone cancer	0.000144	0.0055	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—bone cancer	0.000142	0.00543	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—bone cancer	0.000142	0.00542	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—bone cancer	0.000141	0.00538	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000139	0.00531	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—bone cancer	0.000134	0.00511	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—bone cancer	0.000134	0.0051	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—bone cancer	0.000133	0.00509	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—bone cancer	0.000132	0.00503	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—bone cancer	0.000132	0.00502	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—bone cancer	0.00013	0.00498	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—bone cancer	0.000125	0.00478	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—bone cancer	0.000125	0.00478	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—bone cancer	0.000123	0.00468	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000116	0.00442	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—bone cancer	0.000116	0.00442	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—bone cancer	0.000115	0.00438	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—bone cancer	0.000111	0.00425	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—bone cancer	0.00011	0.00419	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—bone cancer	0.000106	0.00405	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—bone cancer	0.000104	0.00397	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—bone cancer	0.000103	0.00392	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—bone cancer	0.000103	0.00391	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—bone cancer	9.72e-05	0.00371	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—bone cancer	9.64e-05	0.00368	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—bone cancer	9.6e-05	0.00366	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—bone cancer	9.5e-05	0.00363	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—bone cancer	9.09e-05	0.00347	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—bone cancer	8.88e-05	0.00339	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—bone cancer	8.41e-05	0.00321	CcSEcCtD
Ruxolitinib—JAK2—Signaling by PDGF—EGFR—bone cancer	4.41e-05	0.000107	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ATF1—bone cancer	4.4e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MMP9—bone cancer	4.39e-05	0.000106	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—BRAF—bone cancer	4.37e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL3—bone cancer	4.37e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—GNA11—bone cancer	4.32e-05	0.000105	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MMP9—bone cancer	4.32e-05	0.000105	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—EGFR—bone cancer	4.32e-05	0.000104	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP2—bone cancer	4.31e-05	0.000104	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KIT—bone cancer	4.31e-05	0.000104	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MDM2—bone cancer	4.31e-05	0.000104	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KIT—bone cancer	4.3e-05	0.000104	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—SMO—bone cancer	4.29e-05	0.000104	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL3—bone cancer	4.29e-05	0.000104	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KIT—bone cancer	4.28e-05	0.000104	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ATF1—bone cancer	4.27e-05	0.000103	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—PTGS2—bone cancer	4.22e-05	0.000102	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KIT—bone cancer	4.18e-05	0.000101	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—EGFR—bone cancer	4.18e-05	0.000101	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—bone cancer	4.17e-05	0.000101	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KIT—bone cancer	4.17e-05	0.000101	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF1R—bone cancer	4.16e-05	0.000101	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL3—bone cancer	4.16e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RGS1—bone cancer	4.15e-05	0.0001	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GRM4—bone cancer	4.15e-05	0.0001	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—GNA11—bone cancer	4.14e-05	0.0001	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—GNA11—bone cancer	4.08e-05	9.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PLAU—bone cancer	4.07e-05	9.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—EGFR—bone cancer	4.06e-05	9.82e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—BRAF—bone cancer	4.05e-05	9.81e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MDM2—bone cancer	4.05e-05	9.8e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—bone cancer	4.03e-05	9.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KIT—bone cancer	4e-05	9.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4e-05	9.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—JUN—bone cancer	3.99e-05	9.65e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—EGFR—bone cancer	3.95e-05	9.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KIT—bone cancer	3.94e-05	9.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—GNA11—bone cancer	3.93e-05	9.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MET—bone cancer	3.92e-05	9.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—CDK4—bone cancer	3.92e-05	9.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL3—bone cancer	3.92e-05	9.48e-05	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—bone cancer	3.89e-05	9.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.86e-05	9.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ATF1—bone cancer	3.85e-05	9.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ENO2—bone cancer	3.82e-05	9.24e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ATF1—bone cancer	3.79e-05	9.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL3—bone cancer	3.76e-05	9.09e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—JUN—bone cancer	3.75e-05	9.06e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFBR2—bone cancer	3.74e-05	9.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL3—bone cancer	3.7e-05	8.94e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MDM2—bone cancer	3.68e-05	8.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—EGFR—bone cancer	3.67e-05	8.88e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MDM2—bone cancer	3.66e-05	8.87e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MMP9—bone cancer	3.64e-05	8.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GRM1—bone cancer	3.6e-05	8.71e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EGFR—bone cancer	3.58e-05	8.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL3—bone cancer	3.56e-05	8.61e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.55e-05	8.6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EGFR—bone cancer	3.55e-05	8.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—DHFR—bone cancer	3.54e-05	8.57e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—JUN—bone cancer	3.52e-05	8.52e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1R—bone cancer	3.51e-05	8.5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.51e-05	8.48e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EGFR—bone cancer	3.49e-05	8.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MDM2—bone cancer	3.49e-05	8.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SMO—bone cancer	3.45e-05	8.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP9—bone cancer	3.44e-05	8.33e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MMP9—bone cancer	3.43e-05	8.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—bone cancer	3.4e-05	8.22e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MDM2—bone cancer	3.4e-05	8.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KIT—bone cancer	3.39e-05	8.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFBR2—bone cancer	3.39e-05	8.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MDM2—bone cancer	3.39e-05	8.19e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MDM2—bone cancer	3.37e-05	8.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMO—bone cancer	3.35e-05	8.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ATF1—bone cancer	3.33e-05	8.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MDM2—bone cancer	3.29e-05	7.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MDM2—bone cancer	3.28e-05	7.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—bone cancer	3.27e-05	7.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP2—bone cancer	3.27e-05	7.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KIT—bone cancer	3.26e-05	7.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL3—bone cancer	3.25e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMO—bone cancer	3.24e-05	7.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP9—bone cancer	3.24e-05	7.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFBR2—bone cancer	3.21e-05	7.78e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—JUN—bone cancer	3.2e-05	7.74e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—JUN—bone cancer	3.18e-05	7.71e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFBR2—bone cancer	3.16e-05	7.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—MDM2—bone cancer	3.15e-05	7.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GNA11—bone cancer	3.15e-05	7.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EGFR—bone cancer	3.13e-05	7.58e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KIT—bone cancer	3.13e-05	7.58e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MDM2—bone cancer	3.11e-05	7.51e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MMP9—bone cancer	3.1e-05	7.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—EGFR—bone cancer	3.07e-05	7.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNA11—bone cancer	3.06e-05	7.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—JUN—bone cancer	3.03e-05	7.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1R—bone cancer	3.02e-05	7.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KIT—bone cancer	3.02e-05	7.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1R—bone cancer	2.97e-05	7.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNA11—bone cancer	2.97e-05	7.18e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EGFR—bone cancer	2.94e-05	7.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—BRAF—bone cancer	2.94e-05	7.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—JUN—bone cancer	2.94e-05	7.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ATF1—bone cancer	2.93e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—JUN—bone cancer	2.93e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—bone cancer	2.92e-05	7.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—JUN—bone cancer	2.86e-05	6.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL3—bone cancer	2.86e-05	6.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—JUN—bone cancer	2.85e-05	6.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ATF1—bone cancer	2.84e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—BRAF—bone cancer	2.84e-05	6.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—bone cancer	2.78e-05	6.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL3—bone cancer	2.77e-05	6.71e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—bone cancer	2.77e-05	6.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ATF1—bone cancer	2.76e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—bone cancer	2.75e-05	6.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—JUN—bone cancer	2.7e-05	6.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL3—bone cancer	2.69e-05	6.51e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MDM2—bone cancer	2.67e-05	6.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—bone cancer	2.62e-05	6.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KIT—bone cancer	2.58e-05	6.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFBR2—bone cancer	2.57e-05	6.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MDM2—bone cancer	2.57e-05	6.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KIT—bone cancer	2.55e-05	6.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMO—bone cancer	2.54e-05	6.13e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—bone cancer	2.51e-05	6.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KIT—bone cancer	2.5e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—bone cancer	2.5e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NDUFA12—bone cancer	2.49e-05	6.03e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—bone cancer	2.47e-05	5.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MDM2—bone cancer	2.47e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—bone cancer	2.46e-05	5.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFBR2—bone cancer	2.44e-05	5.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KIT—bone cancer	2.43e-05	5.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BRAF—bone cancer	2.4e-05	5.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—bone cancer	2.38e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MDM2—bone cancer	2.38e-05	5.76e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—bone cancer	2.38e-05	5.75e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFBR2—bone cancer	2.37e-05	5.74e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—bone cancer	2.32e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—bone cancer	2.32e-05	5.62e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—JUN—bone cancer	2.32e-05	5.62e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—bone cancer	2.32e-05	5.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNA11—bone cancer	2.32e-05	5.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—bone cancer	2.31e-05	5.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KIT—bone cancer	2.31e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—bone cancer	2.3e-05	5.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFBR2—bone cancer	2.3e-05	5.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1R—bone cancer	2.3e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—bone cancer	2.25e-05	5.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—bone cancer	2.24e-05	5.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1R—bone cancer	2.23e-05	5.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—JUN—bone cancer	2.23e-05	5.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KIT—bone cancer	2.19e-05	5.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BRAF—bone cancer	2.17e-05	5.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1R—bone cancer	2.17e-05	5.24e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KIT—bone cancer	2.16e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ATF1—bone cancer	2.16e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—bone cancer	2.16e-05	5.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—bone cancer	2.12e-05	5.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL3—bone cancer	2.1e-05	5.09e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—bone cancer	2.1e-05	5.09e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—JUN—bone cancer	2.07e-05	5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NT5C3A—bone cancer	2.06e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BRAF—bone cancer	2.06e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MDM2—bone cancer	2.03e-05	4.92e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BRAF—bone cancer	2.03e-05	4.91e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—bone cancer	2.01e-05	4.87e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MDM2—bone cancer	2.01e-05	4.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—bone cancer	2e-05	4.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—bone cancer	1.99e-05	4.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MDM2—bone cancer	1.97e-05	4.77e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—bone cancer	1.97e-05	4.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MDM2—bone cancer	1.91e-05	4.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KIT—bone cancer	1.9e-05	4.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—bone cancer	1.83e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MDM2—bone cancer	1.82e-05	4.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFBR2—bone cancer	1.8e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—JUN—bone cancer	1.77e-05	4.27e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—bone cancer	1.76e-05	4.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—bone cancer	1.75e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KIT—bone cancer	1.75e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JUN—bone cancer	1.75e-05	4.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MDM2—bone cancer	1.73e-05	4.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JUN—bone cancer	1.71e-05	4.15e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MDM2—bone cancer	1.7e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—bone cancer	1.7e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—bone cancer	1.69e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—bone cancer	1.69e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KIT—bone cancer	1.67e-05	4.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JUN—bone cancer	1.66e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—bone cancer	1.65e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—bone cancer	1.64e-05	3.96e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—bone cancer	1.63e-05	3.93e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KIT—bone cancer	1.62e-05	3.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KIT—bone cancer	1.57e-05	3.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—bone cancer	1.57e-05	3.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—bone cancer	1.52e-05	3.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JUN—bone cancer	1.5e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MDM2—bone cancer	1.49e-05	3.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—bone cancer	1.48e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—bone cancer	1.48e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—bone cancer	1.48e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—bone cancer	1.46e-05	3.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—bone cancer	1.44e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—bone cancer	1.39e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MDM2—bone cancer	1.38e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—bone cancer	1.37e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—bone cancer	1.36e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—bone cancer	1.35e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—bone cancer	1.33e-05	3.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MDM2—bone cancer	1.31e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—bone cancer	1.31e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—bone cancer	1.3e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—bone cancer	1.28e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—bone cancer	1.24e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—bone cancer	1.24e-05	2.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—bone cancer	1.23e-05	2.97e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—bone cancer	1.18e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—bone cancer	1.16e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—bone cancer	1.15e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—bone cancer	1.15e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—bone cancer	1.14e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—bone cancer	1.12e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—bone cancer	1.11e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—bone cancer	1.11e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—bone cancer	1.08e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—bone cancer	1.07e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—bone cancer	1.05e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—bone cancer	1.02e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—bone cancer	9.91e-06	2.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—bone cancer	9.75e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—bone cancer	9.66e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—bone cancer	9.43e-06	2.28e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—bone cancer	9.04e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—bone cancer	8.98e-06	2.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—bone cancer	8.71e-06	2.11e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—bone cancer	8.45e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—bone cancer	8.4e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DHFR—bone cancer	8.39e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—bone cancer	8.17e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNA11—bone cancer	7.84e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—bone cancer	7.54e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—bone cancer	7.32e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—bone cancer	7.1e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—bone cancer	6.6e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—bone cancer	6.08e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—bone cancer	5.54e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—bone cancer	3.15e-06	7.62e-06	CbGpPWpGaD
